Anlon Healthcare Limited has seen a significant reduction in stake by Neomile Asset Managers Private Limited through a series of open market transactions. The sales, which took place between November 3-4, 2025, have altered the ownership structure of the healthcare company.

Key Details of the Transaction

Impact on Shareholding

The open market sale has resulted in a notable change in Neomile Asset Managers' position in Anlon Healthcare. Their holding has decreased from 10.40% to 7.62% of the company's total share capital, representing a reduction of 2.78 percentage points.

Transaction Participants

Neomile Growth Fund-Series I was acting in concert with Neomile Corporate Advisory Limited as the seller in these transactions. This coordinated action suggests a strategic move by the Neomile group to adjust their investment in Anlon Healthcare.

Company Listing

Anlon Healthcare maintains its presence on both the National Stock Exchange and Bombay Stock Exchange, providing investors with multiple trading venues for the company's shares.

The reduction in Neomile Asset Managers' stake may attract attention from market participants. However, the immediate impact on Anlon Healthcare's operations or market performance remains to be seen.

Anlon Healthcare Limited has announced a significant development in its product portfolio, revealing the successful creation of two new anti-malarial products. The company, known for its pharmaceutical innovations, is set to introduce Artemether and Lumefantrine to the market in November 2025.

Product Development

The announcement comes as part of Anlon Healthcare's strategic initiative to expand its product range and address the evolving needs of its clientele. The two new products, both targeting malaria treatment, represent a notable advancement in the company's research and development efforts:

• Artemether: An anti-malarial medication
• Lumefantrine: Another anti-malarial drug

Launch Timeline

According to the company's official communication to the stock exchanges, both Artemether and Lumefantrine are scheduled for launch in November 2025. This timeline gives Anlon Healthcare ample opportunity to prepare for the market introduction and potentially set the stage for a strong entry into the anti-malarial segment.

Strategic Implications

The development of these new products aligns with Anlon Healthcare's broader strategy to diversify its offerings and strengthen its position in the pharmaceutical market. By focusing on anti-malarial medications, the company is addressing a critical global health concern, potentially opening up new market opportunities.

Regulatory Compliance

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anlon Healthcare has duly informed the stock exchanges about this significant development. The company has stated that it will provide further updates on these products as developments occur.

Management Statement

Punitkumar Rasadia, Managing Director of Anlon Healthcare Limited, signed off on the regulatory filing, underlining the importance of this announcement to the company's growth trajectory.

Investors and stakeholders will be keenly watching for further updates on these new products as Anlon Healthcare moves closer to the projected launch date.